Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Study of Robot-assisted Radical Prostatectomy Performed on Outpatient in Patients With Localized Prostate Cancer

NCT04319146 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-01-25
Last updated
2025-12-04

Condition(s) studied

Prostate Cancer

Investigational drug(s) / intervention(s)

robot-assisted radical prostatectomy

robot-assisted radical prostatectomy: robot-assisted radical prostatectomy as first-line treatment

Study summary

The promoter propose a pilot study evaluating the feasability of robot-assisted radical prostatectomy on outpatient in patients with localized prostate cancer. This study will enrole a total of 20 patients over one center, followed for 1 month. The total study duration will be 15 months, including statistical analysis and publication.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Men * Older than 18 years old, if\> 70 years old, then patient having had a favorable onco-geriatric consultation (Balducci 2 and life expectancy\> 10 years) * Patient with localized prostate cancer applying for radical prostatectomy treatment * Patient accepting outpatient surgery * Radical prostatectomy performed as first-line treatment * BMI \<35 * ASA score \<3 * Accompanying person available (taxi authorized) to ensure return home * Have quick access to a telephone line * Patient who signed their informed consent * Patient covered by social security or other health insurance Exclusion Criteria: * History of major abdominal surgery * History of pelvic radiotherapy * History of major urogenital malformation * Sleep apnea syndrome * Taking the following drugs within 48 hours (Plavix®, anti-vitamin K / curative LMWH) * Contraindication to ambulatory medical care * Inability to understand and sign the informed consent and to complete the self-questionnaires * Vulnerable people

Primary outcome measure(s)

  • Absence of conventional hospitalization after robot-assisted radical prostatectomy — 24 hours following the intervention

Trial sites (1)

FacilityCityRegionStatus
CHU de NICE Pasteur 2 Nice CHU de Nice
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04319146 on ClinicalTrials.gov ↗ ← All trials in France